Oxford BioMedica Annonces Ocular Programme Update

-- RetinoStat^® Progress in Phase I Study in Wet Age-Related Macular Degeneration --

Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat

is safe and well-tolerated at one month following treatment.  RetinoStat

is a novel gene-based treatment for neovascular “wet” age-related macular degeneration (AMD), designed and developed by Oxford BioMedica using the Company's proprietary LentiVector

gene delivery technology.  It is the lead programme of the ocular agreement the Company signed with Sanofi (EURONEXT: SAN and NYSE: SNY) in April 2009.

Overview